Pathological gambling behavior in a patient with Parkinson's disease treated with levodopa and bromocriptine;Comportement pathologique de jeu au cours d'une maladie de Parkinson traitée par lévodopa et bromocriptine

Revue Neurologique

Volumn 159, Issue 4, 2003, Pages 441-443

  Montastruc, J L ^a,c   Schmitt, L ^b   Bagheri, H ^a  

^a TOULOUSE UNIVERSITY HOSPITAL   (France)

^b CHU PURPAN   (France)

^c UNIVERSITÉ DE TOULOUSE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BENSERAZIDE; BROMOCRIPTINE; CITALOPRAM; DOPAMINE RECEPTOR STIMULATING AGENT; FLUOXETINE; LEVODOPA; TRIHEXYPHENIDYL;

ADULT; AKINESIA; ARTICLE; CASE REPORT; DEPRESSION; DYSKINESIA; FEMALE; HUMAN; MUSCLE HYPERTONIA; PARKINSON DISEASE; PATHOLOGICAL GAMBLING;

ANTIDEPRESSIVE AGENTS; ANTIPARKINSON AGENTS; BROMOCRIPTINE; CITALOPRAM; DEPRESSIVE DISORDER; DOPAMINE AGENTS; FEMALE; FLUOXETINE; GAMBLING; HUMANS; LEVODOPA; MIDDLE AGED; PARKINSON DISEASE;

EID: 0037960123     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. AMERICAN PSYCHIATRIC ASSOCIATION. (1996). Jeu pathologique. In: Mini DSM-IV. Critères diagnostiques (Washington Dc, 1994). Traduction française par JD Guelfi et al., Masson, Paris, 1996, pp 273.
2. BEGAUD B, EVREUX JC, JOUGLARD J, LAGIER G. (1981). Imputabilité des effets inattendus ou toxiques des médicaments. Actualisation de la méthode utilisée en France. Thérapie, 40: 247-251.
3. BERGH C, EKLUND T, SODERSTEN P, NORDIN C. (1997). Altered dopamine function in pathological gambling. Psychol Med, 27: 473-475.
4. DI CHIARA G. (1999). Drug addiction as dopamine-dependent associative learning disorders. Eur J Pharmacol, 375: 13-30.
5. GIOVANNONI G, O'SULLIVAN JD, TURNER K, MANSON AJ, LEES AJL. (2000). Hedonistic homeostatic dysregulation in patients with Parkinson's disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry, 68: 423-428.
6. GSCHWANDTNER U, ASTON J, RENAUD S, FUHR P. (2001). Pathological gambling in patients with Parkinson's disease. Clin Neuropharmacol, 24: 170-172.
7. MOLINA JA, SAINT-ARTIGA MJ, FRAILE A, JIMENEZ-JIMENEZ FJ, VILLANUEVA C, ORTI-PAREJA M, BERMEJO PF. (2000). Pathological gambling in Parkinson's disease: a behavioral manifestation of pharmacological treatment? Mov Disord, 15: 869-872.
8. MONTASTRUC JL, RASCOL O, SENARD JM. (1990). Les médicaments anti-parkinsoniens: bilan et nouvelles perspectives pharmacologiques. Med et Hyg, 48: 11852-11860.
9. MONTASTRUC JL, BAGHERI H, LAPEYRE-MESTRE M, SENARD JM. (1999). Pharmacovigilance et pharmacoépidémiologie: principes, définition, méthodes et actualités en Neurologie. Rev Neurol (Paris), 155: 312-324.
10. NUTT DJ. (1996). Addiction: brain mechanisms and their treatment implications. Lancet, 347: 31-36.
11. PEREZ DE CASTRO I, IBANEZ A, TORRES P et al. (1997). Genetic association study between pathological gambling and a functional DNA polymorphism at the D4 receptor gene. Pharmacogenetics, 7: 345-348.
12. POTENZA MN. (2001). The neurobiology of pathological gambling. Semin Clin Neuropsychiatry, 6: 217-226.
13. PRESCRIRE RÉDACTION. (2001). Des médicaments qui poussent au jeu pathologique. Rev Prescr, 21: 675.
14. SAMANTA J, STACY M. (2000). Compulsive gambling with dopaminergic therapy in Parkinson's disease. Mov Disord, 15: 125.
15. SEEDAT S, KESLER S, NIEHAUS DJH, STEIN DJ. (2000). Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety, 11: 185-186.